Citation
Vaverkova, Helena, et al. "Lipid-altering Efficacy of Ezetimibe/simvastatin 10/20 Mg Compared to Rosuvastatin 10 Mg in High-risk Patients With and Without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy." Cardiovascular Therapeutics, vol. 30, no. 2, 2012, pp. 61-74.
Vaverkova H, Farnier M, Averna M, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther. 2012;30(2):61-74.
Vaverkova, H., Farnier, M., Averna, M., Missault, L., Viigimaa, M., Dong, Q., Shah, A., Johnson-Levonas, A. O., & Brudi, P. (2012). Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovascular Therapeutics, 30(2), 61-74. https://doi.org/10.1111/j.1755-5922.2010.00181.x
Vaverkova H, et al. Lipid-altering Efficacy of Ezetimibe/simvastatin 10/20 Mg Compared to Rosuvastatin 10 Mg in High-risk Patients With and Without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. Cardiovasc Ther. 2012;30(2):61-74. PubMed PMID: 20626402.
TY - JOUR
T1 - Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
AU - Vaverkova,Helena,
AU - Farnier,Michel,
AU - Averna,Maurizio,
AU - Missault,Luc,
AU - Viigimaa,Margus,
AU - Dong,Qian,
AU - Shah,Arvind,
AU - Johnson-Levonas,Amy O,
AU - Brudi,Philippe,
Y1 - 2010/07/07/
PY - 2010/7/15/entrez
PY - 2010/7/16/pubmed
PY - 2012/7/4/medline
SP - 61
EP - 74
JF - Cardiovascular therapeutics
JO - Cardiovasc Ther
VL - 30
IS - 2
N2 - AIMS: This post hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in uncontrolled high-risk hypercholesterolemic patients with/without type 2 diabetes mellitus (T2DM) despite statin monotherapy. METHODS: Patients (n = 618) at high risk for coronary vascular disease with elevated LDL-C ≥100 and ≤190 mg/dL despite use of statins were randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as having T2DM based on ≥1 of the following: diagnosis of T2DM, antidiabetic medication, or FPG ≥126 mg/dL. This analysis evaluated percent changes from baseline in lipids among patients with (n = 182) and without T2DM (n = 434). RESULTS: EZE/SIMVA was more effective than ROSUVA at lowering LDL-C, TC, non-HDL-C, and apo B in the overall study population and within both subgroups. Numerically, greater between-treatment reductions in LDL-C, TC, non-HDL-C, and apo B were seen in patients with T2DM versus those without T2DM. A significant interaction (P= 0.015) was seen for LDL-C indicating that patients with T2DM achieved larger between-group reductions versus those without T2DM. CONCLUSIONS: Switching to EZE/SIMVA 10/20 mg versus ROSUVA 10 mg provided superior lipid reductions in patients with/without T2DM.
SN - 1755-5922
UR - https://www.unboundmedicine.com/medline/citation/20626402/Lipid_altering_efficacy_of_ezetimibe/simvastatin_10/20_mg_compared_to_rosuvastatin_10_mg_in_high_risk_patients_with_and_without_type_2_diabetes_mellitus_inadequately_controlled_despite_prior_statin_monotherapy_
L2 - https://doi.org/10.1111/j.1755-5922.2010.00181.x
DB - PRIME
DP - Unbound Medicine
ER -
